Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02420977 · ClinicalTrials.gov registry record · Early Phase 1
Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer
A Early Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 23
- Enrollment target
NCT02420977 is a Early Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 23 participants.
The verdict
NCT02420977, a Early Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This research is being done to see if an investigational radioactive imaging agent (radiotracer) called 18F-DCFPyL can help us find prostate cancer at its original site in the prostate gland and in distant sites (bone, lymph nodes) in men diagnosed with prostate cancer before surgery.
Interventions
- DRUG Pelvic DCFPyL PET-MRI fusion or PET/MRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2018-12-06 |
| Est. Completion | 2025-03-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02420977
The ClinicalTrials.gov registry entry for NCT02420977 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pelvic DCFPyL PET-MRI fusion or PET/MRI is the first listed.
NCT02420977 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02420977 about?
NCT02420977 is a clinical study titled "Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer". This research is being done to see if an investigational radioactive imaging agent (radiotracer) called 18F-DCFPyL can help us find prostate cancer at its original site in the prostate gland and in distant sites (bone, lymph nodes) in men diagnosed with prostate cancer before surgery.
What is the current status of trial NCT02420977?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 23 participants. The study started on 2018-12-06. Estimated completion is 2025-03-01.
What interventions are being tested in trial NCT02420977?
The interventions under investigation include: Pelvic DCFPyL PET-MRI fusion or PET/MRI (DRUG).
Who is sponsoring clinical trial NCT02420977?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.